Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,526 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Chronic Graft-Versus-Host-Disease Clear all

Conditions: Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions: CC-10004; Drug
Lead sponsor: Kenneth Peters, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Childhood Cancer, Cerebral Palsy, Chronic Lung Disease, Congenital Heart Disease, Congenital Metabolic Disorder, Gastrostomy
Interventions: GoalKeeper, Standard Care; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Chronic Low-back Pain
Interventions: Flowly (TMC-CP01); Device
Lead sponsor: Ajay Wasan, MD, Msc; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions: SUN-627, Placebo; Drug · Other
Lead sponsor: Sundance Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Stony Brook, New York + 4 more

Conditions: Congestive Heart Failure Chronic, Low Ejection Fraction
Interventions: Heartlogic Diagnostic Tool Threshold Change, Heartlogic Diagnostic Tool Unchanged Threshold; Device
Lead sponsor: Robert Pickett; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Indianapolis, Indiana • Nashville, Tennessee

Conditions: Prostatic Neoplasms
Interventions: Registry; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia Associated Pulmonary Hypertension, Pulmonary Hypertension, Premature Birth, Chronic Lung Disease of Prematurity
Interventions: Enteral L-citrulline; Dietary Supplement
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: Up to 30 Weeks
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Acute Low Back Pain, Chronic Low Back Pain
Interventions: Not listed
Lead sponsor: University of Parma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: End-Stage Renal Disease (ESRD)
Interventions: EPN-701 (Oral); Drug
Lead sponsor: Epizon Pharma, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Post-Acute COVID-19 Syndrome
Interventions: NeuroFlex (computerized gamified tasks); Other
Lead sponsor: UConn Health; Other
Eligibility: 60 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Alagille Syndrome, Cholestasis, Biliary Atresia
Interventions: magnesium gluconate, magnesium sulfate; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 3 Years to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Kidney Disease
Interventions: Propranolol, Losartan, Eprosartan; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Pain
Interventions: Headspace app; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Pain, Soft Tissue Injuries, Wound Heal, Blood Flow
Interventions: Laser Doppler, Radiofrequency Heating System, Thermal Imaging, Healthcare Questionnaire & Measurement; Device · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hepatitis Delta Virus
Interventions: Peginterferon Lambda-1a; Drug
Lead sponsor: Eiger BioPharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Los Angeles, California • Redwood City, California • San Francisco, California + 2 more

Conditions: Glaucoma, Open-Angle
Interventions: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution); Drug
Lead sponsor: Mankind Pharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Bakersfield, California • Mission Hills, California • Newport Beach, California + 5 more

Conditions: Chronic Pain, Osteoarthritis
Interventions: Transcranial Direct Current Stimulation; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Insomnia
Interventions: SleepScore Max coaching feature, Online CBTi; Device · Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
Interventions: Oxycodone CR, Tapentadol (CG5503) ER; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 40
States / cities: Mesa, Arizona • Tucson, Arizona • Anaheim, California + 37 more

Conditions: Schizophrenia
Interventions: Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 61 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more

Conditions: Pain, Postoperative, Pain, Chronic, Pain, Acute, Surgical Injury, Surgical Wound, Cornea Injury, Cornea, Keratoconus
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Patient Education; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Orelabrutinib, Placebo; Drug
Lead sponsor: Zenas BioPharma (USA), LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 27
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 23 more

Conditions: End-Stage Renal Disease
Interventions: exposure to a high-calcium dialysate bath; Procedure
Lead sponsor: James B. Wetmore, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

GoalKeeper: Intelligent Information Sharing for Children With Medical Complexity

VANISH for Chronic Low Back Pain

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

Evaluation of the HeartLogic Diagnostic in Optimizing Guideline-directed Medical Therapy in Patients With Congestive Heart Failure and Chronically Low Ejection Fractions (EFs)

An Electronic Registry to Improve Adherence to Active Surveillance Monitoring at a Safety-net Hospital

Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing

A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain

A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)

Brain-Training Treatment for Long COVID in Older Adults

Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease

Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers

Meditation for Pain

Radiofrequency Hyperthermia Safety Study

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

Effects of Transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound on Osteoarthritis Pain of the Knee

Naturalistic Monitoring and Treatment of Chronic Insomnia

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

A Study of Cariprazine in Patients With Chronic Stable Schizophrenia

fMRI and IVCM Cornea Microscopy of CXL in Keratoconus

Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients